UBS downgraded enGene (ENGN) to Neutral from Buy with a price target of $7, down from $34, after assuming coverage of the name. enGene’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback